Menu
← Oncology Approval Tracker
FDA DECISION ·
Elahere
mirvetuximab soravtansine-gynx · ImmunoGen
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with FRα-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three previous systemic regimens, selected using an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
The original accelerated approval introduces FRα-directed therapy after platinum resistance.
What research teams should watch
Verify the assay and prior-line count. Coordinate eye examinations and ocular toxicity reporting.
PRIMARY RECORDS